Results for "Pembrolizumab"

The Indian drugmaker partnered with a Chinese rival to license and distribute a pembrolizumab biosimilar, expanding its footprint in the lucrative oncology market.

AIM ImmunoTech has been granted a broad U.S. patent covering the use of Rintatolimod (Ampligen) combined with Pembrolizumab (Keytruda), extending intellectual property rights for the oncology treatment.

Immunotherapy with pembrolizumab has led to a significant reduction in thousands of oncological deaths and cancer metastases in Greece between 2017 and 2024, according to a Greek study presented at the 8th Hellenic Oncology Congress.

Thousands of cancer patients in England are set to receive a new injectable immunotherapy treatment, pembrolizumab, which can treat several types of cancer and be administered in under two minutes.

Clinical trial results indicate that Summit Therapeutics’ investigational drug ivonescimab meets key secondary endpoints for overall survival in non-small cell lung cancer patients. The promising interim data positions the treatment as a potential new standard in first-line therapy.

A significant advancement in the treatment of muscle-invasive bladder cancer (MIBC) has been published in the New England Journal of Medicine, highlighting the superior efficacy of enfortumab vedotin and pembrolizumab combination therapy over chemotherapy.

Patients in a new bowel cancer immunotherapy trial have remained cancer-free for nearly three years after receiving pembrolizumab before surgery, marking a significant breakthrough.

An interim analysis of the Phase III HARMONi-2 study reveals that ivonescimab meets key secondary endpoints for overall survival, demonstrating clinically meaningful benefits compared to pembrolizumab in first-line PD-L1-positive non-small cell lung cancer patients.

The European Union has approved a new combination therapy of pembrolizumab and enfortumab vedotin-ejfv for adult patients with surgically resectable bladder cancer, which has shown to reduce the risk of death by 50%.

The UK is introducing an injectable form of pembrolizumab for cancer treatment, which is expected to significantly reduce the time patients spend in hospitals compared to intravenous administration.